ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
P3.01-073 TPX-0005 with an EGFR Tyrosine Kinase Inhibitor (TKI) Overcomes Innate Resistance in EGFR Mutant NSCLC
Journal of Thoracic Oncology
◽
10.1016/j.jtho.2017.09.1514
◽
2017
◽
Vol 12
(11)
◽
pp. S2230
Author(s):
R. Rosell
◽
N. Karachaliou
◽
J.J. Cui
◽
I. Chaib
◽
J. Berenguer
◽
...
Keyword(s):
Tyrosine Kinase
◽
Tyrosine Kinase Inhibitor
◽
Kinase Inhibitor
◽
Egfr Tyrosine Kinase Inhibitor
◽
Innate Resistance
◽
Egfr Tyrosine Kinase
◽
Egfr Mutant
Download Full-text
Related Documents
Cited By
References
EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC
Journal of Thoracic Oncology
◽
10.1016/j.jtho.2021.08.015
◽
2021
◽
Vol 16
(11)
◽
pp. 1793-1797
Author(s):
Sophie Stock-Martineau
◽
Frances A. Shepherd
Keyword(s):
Tyrosine Kinase
◽
Tyrosine Kinase Inhibitor
◽
Kinase Inhibitor
◽
Line Treatment
◽
First Line
◽
Egfr Tyrosine Kinase Inhibitor
◽
Egfr Tyrosine Kinase
◽
Egfr Mutant
◽
First Line Treatment
Download Full-text
Targeting c-Myc to overcome acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR tyrosine kinase inhibitor, osimertinib
Cancer Research
◽
10.1158/0008-5472.can-21-0556
◽
2021
◽
pp. canres.0556.2021
Author(s):
Lei Zhu
◽
Zhen Chen
◽
Hongjing Zang
◽
Songqing Fan
◽
Jiajia Gu
◽
...
Keyword(s):
Tyrosine Kinase
◽
Tyrosine Kinase Inhibitor
◽
Kinase Inhibitor
◽
Acquired Resistance
◽
Third Generation
◽
Egfr Tyrosine Kinase Inhibitor
◽
The Third
◽
Egfr Tyrosine Kinase
◽
Egfr Mutant
Download Full-text
Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma
OncoTargets and Therapy
◽
10.2147/ott.s62639
◽
2014
◽
pp. 799
◽
Cited By ~ 9
Author(s):
Jeng-Sen Tseng
◽
Tsung-Ying Yang
◽
Kun-Chieh Chen
◽
Kuo-Hsuan Hsu
◽
Chong-Jen Yu
◽
...
Keyword(s):
Tyrosine Kinase
◽
Lung Adenocarcinoma
◽
Tyrosine Kinase Inhibitor
◽
Kinase Inhibitor
◽
Inhibitor Therapy
◽
Egfr Tyrosine Kinase Inhibitor
◽
Egfr Tyrosine Kinase
◽
Tyrosine Kinase Inhibitor Therapy
◽
Egfr Mutant
Download Full-text
Reduced chemotherapy sensitivity in EGFR-mutant lung cancer patient with frontline EGFR tyrosine kinase inhibitor
Lung Cancer
◽
10.1016/j.lungcan.2014.09.008
◽
2014
◽
Vol 86
(2)
◽
pp. 219-224
◽
Cited By ~ 10
Author(s):
Zhu Zeng
◽
Hong-hong Yan
◽
Xu-chao Zhang
◽
Wen-zhao Zhong
◽
Yan-yan He
◽
...
Keyword(s):
Lung Cancer
◽
Cancer Patient
◽
Tyrosine Kinase
◽
Tyrosine Kinase Inhibitor
◽
Lung Cancer Patient
◽
Kinase Inhibitor
◽
Egfr Tyrosine Kinase Inhibitor
◽
Chemotherapy Sensitivity
◽
Egfr Tyrosine Kinase
◽
Egfr Mutant
Download Full-text
Active or Attractive? Oral Antiangiogenesis Therapy Plus EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant NSCLC
Journal of Thoracic Oncology
◽
10.1016/j.jtho.2021.06.028
◽
2021
◽
Vol 16
(9)
◽
pp. 1426-1428
Author(s):
Bin-Chi Liao
◽
James Chih-Hsin Yang
Keyword(s):
Tyrosine Kinase
◽
Tyrosine Kinase Inhibitor
◽
Kinase Inhibitor
◽
Egfr Tyrosine Kinase Inhibitor
◽
Egfr Tyrosine Kinase
◽
Antiangiogenesis Therapy
◽
Egfr Mutant
Download Full-text
Dual-agent molecular targeting of growth factor receptors in hepatocellular cancer: Combining anti-EGFR antibody with an EGFR tyrosine kinase inhibitor
Zeitschrift für Gastroenterologie
◽
10.1055/s-2005-920152
◽
2005
◽
Vol 43
(05)
◽
Author(s):
A Hüther
◽
M Höpfner
◽
D Schuppan
◽
H Scherübl
Keyword(s):
Growth Factor
◽
Tyrosine Kinase
◽
Tyrosine Kinase Inhibitor
◽
Kinase Inhibitor
◽
Hepatocellular Cancer
◽
Growth Factor Receptors
◽
Molecular Targeting
◽
Egfr Tyrosine Kinase Inhibitor
◽
Egfr Tyrosine Kinase
◽
Egfr Antibody
Download Full-text
Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI
Case Medical Research
◽
10.31525/ct1-nct04007835
◽
2019
◽
Author(s):
Keyword(s):
Tyrosine Kinase
◽
Tyrosine Kinase Inhibitor
◽
Advanced Nsclc
◽
Kinase Inhibitor
◽
Acquired Resistance
◽
Egfr Tyrosine Kinase Inhibitor
◽
Egfr Tyrosine Kinase
◽
Nsclc Patients
◽
Egfr Tki
Download Full-text
O-247 Molecular mechanisms of sensitivity and resistance to the HER1/EGFR-tyrosine kinase inhibitor erlotinib (Tarceva™)
Lung Cancer
◽
10.1016/s0169-5002(03)91905-2
◽
2003
◽
Vol 41
◽
pp. S72
◽
Cited By ~ 6
Author(s):
Roman Perez-Soler
◽
Qun Dai
◽
Yi-He Ling
◽
Marie Lee
◽
Glenn Kroog
◽
...
Keyword(s):
Tyrosine Kinase
◽
Tyrosine Kinase Inhibitor
◽
Molecular Mechanisms
◽
Kinase Inhibitor
◽
Egfr Tyrosine Kinase Inhibitor
◽
Egfr Tyrosine Kinase
Download Full-text
Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
Molecular Cancer Therapeutics
◽
10.1158/1535-7163.mct-11-0048
◽
2011
◽
Vol 10
(6)
◽
pp. 1102-1112
◽
Cited By ~ 113
Author(s):
Monika E. Hegi
◽
Annie-Claire Diserens
◽
Pierre Bady
◽
Yuta Kamoshima
◽
Mathilde C. M. Kouwenhoven
◽
...
Keyword(s):
Tyrosine Kinase
◽
Tyrosine Kinase Inhibitor
◽
Phase Ii
◽
Pathway Analysis
◽
Kinase Inhibitor
◽
Phase Ii Trial
◽
Preoperative Treatment
◽
Egfr Tyrosine Kinase Inhibitor
◽
Egfr Tyrosine Kinase
Download Full-text
Egfr-Tyrosine Kinase Inhibitor (Tki) Rechallenge with Bevacizumab in Egfr-Mutant Non-Small Cell Lung Cancer (Nsclc)
Annals of Oncology
◽
10.1093/annonc/mdu349.65
◽
2014
◽
Vol 25
◽
pp. iv452
Author(s):
K. Otsuka
◽
A. Hata
◽
R. Kato
◽
J. Takeshita
◽
C. Okuda
◽
...
Keyword(s):
Lung Cancer
◽
Tyrosine Kinase
◽
Small Cell Lung Cancer
◽
Tyrosine Kinase Inhibitor
◽
Cell Lung Cancer
◽
Kinase Inhibitor
◽
Small Cell
◽
Small Cell Lung
◽
Egfr Tyrosine Kinase Inhibitor
◽
Egfr Mutant
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close